innerbuddies gut microbiome testing

Gut Microbiome in IBD-Unclassified: How Microbiota Shapes Inflammation and Symptoms

If you’ve been told you have IBD-unclassified (IBD-U), it often means the inflammation is real—but the exact pattern of disease doesn’t yet fit neatly into ulcerative colitis or Crohn’s disease. In many people, that “in-between” state is closely tied to the gut microbiome: trillions of microbes that help break down food, train the immune system, and maintain the intestinal barrier. When the balance of these communities shifts, it can tilt the gut environment toward ongoing inflammation and variable symptoms.

Research suggests that dysbiosis in IBD-U may involve reduced microbial diversity, altered populations of bacteria that produce beneficial metabolites (like short-chain fatty acids), and changes in pathways that affect gut barrier function and immune signaling. Rather than a single “bad germ,” it’s more often a network effect—microbes and their metabolites interacting with the mucus layer, epithelial cells, and immune responses. That can help explain why symptoms such as diarrhea, abdominal pain, urgency, or fatigue can fluctuate and why inflammation may persist even when standard tests are inconclusive.

The encouraging part: as clinicians evaluate inflammation patterns, biomarkers, imaging, and stool studies, microbiome insights are increasingly used to understand what’s driving your symptoms and how to guide treatment. Nutrition strategies, targeted therapies, and microbiome-supporting approaches may help encourage a healthier ecosystem—strengthening the barrier, modulating immune responses, and reducing inflammatory triggers. Understanding your gut microbiota can be a powerful step toward clearer diagnosis, more personalized care, and gut healing in IBD-unclassified.

Order Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

IBD-unclassified

IBD-U, or inflammatory bowel disease-unclassified, describes cases where disease activity is present but does not yet meet clear criteria for Crohn’s disease (CD) or ulcerative colitis (UC). Across patients, the gut microbiome often shows dysbiosis—reduced diversity and a shift away from butyrate-producing taxa—that can weaken the mucus layer and epithelial barrier and sustain inflammation through altered microbial metabolism and immune signaling. This overlap in microbial patterns with CD-like and UC-like biology helps explain why the diagnosis remains unclassified early on and why microbiome profiling is increasingly explored to guide prognosis and treatment.

Functional microbiome tests, such as profiling microbial metabolism and short-chain fatty acid outputs, can reveal deficits in butyrate production and related pathways even when endoscopy or histology is not definitive. Such findings support personalized gut-healing strategies, including nutrition optimization and microbiome-targeted therapies, and may help stratify patients by likely disease trajectory and flare risk. The InnerBuddies test exemplifies this approach by highlighting not only which microbes are present but what they are doing, emphasizing fermentation pathways and barrier-supporting metabolites.

In IBD-U, common symptoms—diarrhea, abdominal pain, bloating, fatigue, and sometimes weight loss—reflect underlying dysbiosis and immune activation. While prevalence estimates place IBD-U as a minority of IBD cases, microbiome patterns can still provide actionable context for management, prognosis, and personalized care, particularly during the period when disease classification may evolve toward CD or UC.

  • Loss of butyrate-producing taxa (e.g., Faecalibacterium prausnitzii, Roseburia spp., Eubacterium rectale/hallii, Anaerostipes, Coprococcus) → reduced butyrate production, weakening mucus layer and epithelial barrier, promoting inflammation.
  • Reduction of Akkermansia muciniphila (mucin-associated barrier support) → thinner mucus layer and greater epithelial vulnerability.
  • Expansion of pro-inflammatory taxa including Escherichia coli / AIEC, Enterococcus spp., Streptococcus spp. → enhanced cytokine signaling and gut inflammation.
  • Increase of Ruminococcus gnavus group → mucin degradation and inflammatory metabolite production contributing to immune activation.
  • Rise of Fusobacterium spp. and non–polysaccharide A–dominant Bacteroides spp. → altered bile-acid metabolism and inflammatory signaling.
  • Depletion of immunoregulatory Bacteroides fragilis (polysaccharide A–positive strains) → reduced Treg induction and loss of mucosal immune tolerance.
Order Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Inflammatory bowel disease (IBD)

IBD-unclassified (IBD-U) refers to cases where inflammatory bowel disease is present but does not yet fit neatly into Crohn’s disease or ulcerative colitis. In this setting, the gut microbiome often shows an “imbalance” (dysbiosis) characterized by reduced microbial diversity and shifts in beneficial vs. inflammatory communities. These changes can influence how the intestinal immune system recognizes and reacts to gut contents, potentially sustaining chronic inflammation even when endoscopic and histologic patterns are not fully established.

A key way the microbiome may shape symptoms and inflammatory activity is through altered microbial metabolic outputs. Beneficial microbes help produce short-chain fatty acids (especially butyrate) that support the intestinal barrier and help regulate immune responses. In IBD-U, decreased butyrate-producing taxa and disrupted fermentation pathways may weaken the mucus layer and epithelial barrier, making it easier for luminal triggers to interact with the immune system. Meanwhile, increased microbial activity that yields pro-inflammatory signals (e.g., altered bile acid transformations or shifts in microbial-derived immune modulators) may further promote cytokine-driven inflammation.

Current research suggests that microbiome patterns can overlap between Crohn’s-like and colitis-like biology, which may partly explain why IBD-U remains undefined initially. Microbial signatures—such as specific community compositions, functional pathways (including carbohydrate and bile acid metabolism), and microbial resilience—may help stratify patients by likely disease trajectory and expected treatment response. As such, microbiome profiling and functional biomarkers are increasingly being explored as tools to support diagnosis, predict flare risk, and guide personalized gut-healing strategies (including nutrition optimization and, in selected cases, microbiome-directed therapies).

  • Chronic or recurrent diarrhea (with or without urgency)
  • Abdominal pain or cramping
  • Blood or mucus in stool
  • Unintentional weight loss
  • Fatigue and reduced energy
  • Anemia-related symptoms (e.g., weakness, lightheadedness) from chronic inflammation
  • Fever or night sweats during flare-ups
  • Bloating and altered bowel habits (constipation or alternating constipation/diarrhea)
Order Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

IBD-unclassified

This information is relevant for people who have been diagnosed with inflammatory bowel disease unclassified (IBD-U)—meaning they have clear signs of intestinal inflammation, but their disease pattern doesn’t fully match Crohn’s disease or ulcerative colitis yet. It’s especially useful for patients and clinicians who want to understand why symptoms may persist even when standard endoscopy and biopsy findings are not definitive, and who are looking for additional ways to characterize the condition beyond the initial “unclassified” label.

It is also relevant for individuals experiencing ongoing or recurrent gut symptoms typical of IBD-U, such as chronic diarrhea (with or without urgency), abdominal cramping, blood or mucus in stool, bloating, and weight loss or fatigue. Because IBD-U often involves gut dysbiosis—reduced microbial diversity and shifts in microbial communities—these pages can help connect symptom experiences with the idea that microbial metabolic outputs (like reduced butyrate production) may weaken the gut barrier and contribute to sustained immune activation.

Finally, this is relevant for patients who are exploring prognosis or more personalized care, including those concerned about flare risk, response to treatment, or long-term gut healing strategies. Microbiome profiling and functional biomarkers (e.g., carbohydrate and bile acid metabolism patterns, barrier-supporting microbial functions, and community resilience) may help stratify patients with IBD-U by likely disease trajectory, potentially guiding nutrition optimization and—where appropriate—future microbiome-directed therapies.

IBD-unclassified (IBD-U) is an important but relatively heterogeneous category within inflammatory bowel disease. Because IBD-U is diagnosed when Crohn’s disease (CD) or ulcerative colitis (UC) criteria are not yet fully met, its prevalence varies widely by region, referral patterns, and how long patients are followed before reclassification. Across population-based and cohort studies, IBD-U is commonly reported as a minority subset of all IBD cases—frequently in the range of roughly 5–15% of newly diagnosed or overall IBD patients—with some cohorts estimating higher proportions early in the disease course (when classification is still evolving).

In terms of symptoms, people with IBD-U often experience the same “core IBD” complaints that drive evaluation for IBD in the first place—most notably chronic or recurrent diarrhea (sometimes with urgency), abdominal pain or cramping, and blood or mucus in stool. Additional symptoms such as fatigue, weight loss, anemia-related complaints, and flare-associated fever/night sweats can also occur. Clinically, these symptom patterns create a significant overlap with either CD-leaning or UC-leaning phenotypes, which is one reason the diagnosis may remain “unclassified” initially and later shift toward CD or UC as inflammation distribution, endoscopic findings, and histology become clearer.

From a microbiome perspective, the dysbiosis seen in IBD-U (e.g., reduced microbial diversity and altered fermentation/metabolic pathways that may affect short-chain fatty acid—particularly butyrate—production) is thought to contribute to persistent immune activation and gut-barrier vulnerability. However, estimating how common specific microbiome patterns are across IBD-U patients is still an emerging area, and prevalence estimates for “microbiome-defined IBD-U” are not yet established in the way that clinical IBD-U prevalence is. Overall, available clinical data support that IBD-U represents a meaningful minority (often around 1 in 10 IBD patients, depending on cohort and follow-up duration), and patients typically present with a blended symptom profile that can later become more clearly CD- or UC-like.

Order Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome in IBD-Unclassified: How It Influences Inflammation and Symptoms

IBD-unclassified (IBD-U) is characterized by inflammatory bowel disease that doesn’t yet clearly match Crohn’s disease or ulcerative colitis, and microbiome research suggests it may still reflect a distinct pattern of gut dysbiosis. In many people with IBD-U, studies show reduced microbial diversity and shifts in key community members, including fewer butyrate-producing organisms. Because these beneficial microbes help maintain intestinal barrier integrity and immune balance, their loss may make the gut lining less resilient to luminal triggers, contributing to ongoing symptoms even when endoscopic or biopsy findings are not fully definitive.

A major way the microbiome can influence IBD-U is through altered microbial metabolism. When fermentation pathways are disrupted, lower production of short-chain fatty acids—especially butyrate—can weaken the mucus layer and impair epithelial tight-junction function. This may allow microbes and dietary components to interact more directly with the immune system, promoting cytokine signaling and sustained inflammation that aligns with common symptoms such as chronic or recurrent diarrhea, abdominal pain or cramping, bloating, and fatigue.

Microbiome functional changes may also affect inflammatory tone through immune-modulating metabolites, including microbial-derived signals that influence how gut immune cells respond to the intestinal environment. In IBD-U, microbial patterns can overlap between Crohn’s-like and colitis-like biology, which may help explain why the condition remains “unclassified” early on. As a result, microbiome profiling and functional biomarkers are increasingly explored to help stratify patients by likely disease trajectory, flare risk, and treatment responsiveness—supporting more personalized nutrition and microbiome-targeted gut-healing strategies.

Order Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome and IBD-unclassified

  • Loss of microbial diversity and beneficial butyrate-producing taxa, weakening mucus and epithelial barrier integrity
  • Reduced short-chain fatty acid (SCFA) production—especially butyrate—leading to impaired tight-junction function and increased immune exposure to luminal triggers
  • Altered microbial fermentation and bile-acid metabolism that shifts luminal metabolites, promoting a more pro-inflammatory immune tone
  • Microbiome-derived metabolites and microbial products (e.g., altered endotoxin/antigen signals) that drive cytokine signaling and sustain gut inflammation
  • Immune-microbe crosstalk changes, including impaired regulation of regulatory T cells and altered responses of Th17/Treg balance
  • Disrupted microbial ecosystem stability and recovery (resilience/resistance), increasing susceptibility to flares and persistent symptoms in IBD-U
  • Overlapping Crohn’s-like and colitis-like microbial functional pathways that may contribute to why disease remains unclassified early on

IBD-unclassified (IBD-U) is inflammatory bowel disease that doesn’t yet fit cleanly into Crohn’s disease or ulcerative colitis. Microbiome studies suggest that, even early on, many people with IBD-U show a dysbiotic gut ecosystem—often marked by reduced microbial diversity and fewer butyrate-producing organisms. Because butyrate helps support the intestinal barrier, mucus protection, and immune tolerance, losing these beneficial microbes can make the gut lining less resilient to normal luminal triggers, contributing to ongoing symptoms such as diarrhea, abdominal pain, bloating, and fatigue.

A key microbiome mechanism is disrupted microbial metabolism, especially fermentation that normally produces short-chain fatty acids (SCFAs) like butyrate. When SCFA output drops, epithelial tight junction function can weaken, and the mucus layer may become less effective at shielding immune cells from microbial and dietary antigens in the gut lumen. In this context, altered luminal metabolites can promote a more pro-inflammatory immune environment, sustaining cytokine signaling and inflammation even when diagnostic findings are not definitive—helping explain persistent or recurrent symptoms characteristic of IBD-U.

Microbial ecosystem changes also influence immune–microbe crosstalk and recovery from flare-like stress. In IBD-U, shifts in microbial community stability and metabolism can alter bile-acid processing and increase immune-stimulating signals (such as endotoxin/antigen exposures), which may disrupt regulatory pathways including Treg control and shift the Th17/Treg balance toward inflammation. Because functional pathways can overlap between Crohn’s-like and colitis-like biology, microbiome-driven differences may contribute to why the condition remains “unclassified” initially and may affect trajectory and treatment responsiveness.

Order Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Microbial patterns summary

In IBD-unclassified (IBD-U), microbiome profiling often reveals a gut ecosystem that looks dysbiotic even early in the disease course. Common findings include reduced overall microbial diversity and shifts away from beneficial community members, particularly organisms that contribute to barrier-supporting metabolites such as butyrate. Because these butyrate-producing microbes help maintain epithelial tight junction integrity and reinforce the mucus layer, their depletion can make the intestinal lining more vulnerable to luminal stressors and antigen exposure, aligning with persistent gastrointestinal symptoms such as diarrhea, abdominal discomfort, bloating, and fatigue.

A central microbial pattern involves altered metabolic function, especially changes to fermentation pathways that normally generate short-chain fatty acids (SCFAs) like butyrate. When SCFA production declines, the protective biochemical environment of the gut may weaken, reducing mucosal resilience and impairing epithelial recovery. This can increase direct immune contact with microbial and dietary signals in the lumen, promoting cytokine-driven inflammatory tone and sustaining immune activation even when standard diagnostic features do not clearly separate the condition into Crohn’s disease or ulcerative colitis.

IBD-U also shows functional and compositional overlap with both Crohn’s-like and colitis-like biology, suggesting that the microbiome may not map neatly to a single subtype early on. Beyond SCFAs, dysbiosis can influence immune–microbe signaling through microbial-derived metabolites and altered handling of microbial products such as bile-acid components and antigenic stimuli. These changes may disrupt regulatory pathways (including Treg-associated tolerance) and skew immune balance toward inflammatory signaling, which can contribute to flare susceptibility and variable treatment response while the disease remains “unclassified.”


Low beneficial taxa

  • Faecalibacterium prausnitzii (butyrate-producing; reduced in IBD-U dysbiosis)
  • Roseburia spp. (butyrate-producing; supports epithelial health)
  • Eubacterium rectale / Eubacterium hallii group (SCFA producers incl. butyrate)
  • Anaerostipes spp. (butyrate-producing; mucus/epithelial support)
  • Coprococcus spp. (SCFA/fermentation-associated; often depleted)
  • Bacteroides fragilis (especially strains with polysaccharide A—immunoregulatory)
  • Akkermansia muciniphila (mucin-associated barrier support; often reduced/imbalanced)


Elevated / overrepresented taxa

  • Escherichia coli / adherent-invasive E. coli (AIEC)-like strains
  • Enterococcus spp.
  • Streptococcus spp.
  • Ruminococcus gnavus group
  • Fusobacterium spp.
  • Bacteroides spp. (non–polysaccharide A–dominant strains; bile-acid and inflammatory potential)
  • Veillonella spp.
  • Dialister spp.


Functional pathways involved

  • Butyrate (SCFA) and other short-chain fatty acid fermentation via anaerobic carbohydrate metabolism
  • Mucin and complex glycan degradation with impacts on mucus-barrier integrity and epithelial protection
  • Bile acid metabolism and bile acid–microbiome conversion pathways (including effects on FXR/TGR5 immune signaling)
  • Protein and amino-acid fermentation generating potentially pro-inflammatory metabolites (e.g., indoles, phenols, branched-chain metabolites)
  • Lipopolysaccharide (LPS)/endotoxin-related inflammatory signaling capacity from Gram-negative microbiota products
  • Microbial antigen processing and presentation-related immune activation pathways (microbe-associated molecular patterns to host signaling)
  • Regulatory metabolite pathways that support Treg/tolerance (SCFA-driven immunomodulation, especially butyrate-mediated effects)


Diversity note

In IBD-unclassified (IBD-U), gut microbiome studies commonly find reduced microbial diversity, even early in the disease course. This loss of diversity often comes with a restructuring of the community, where the ecosystem becomes less stable and less able to resist environmental and dietary stressors in the gut. As beneficial taxa decline and the relative abundance of other organisms increases, the overall balance of microbial interactions shifts, which can align with persistent symptoms like diarrhea, cramping, bloating, and fatigue.

A key theme tied to lower diversity in IBD-U is a decrease in microbes that support barrier health through fermentation-related metabolism. Many of these organisms contribute to short-chain fatty acid (SCFA) production—particularly butyrate—which helps maintain the mucus layer and supports epithelial tight junction function. When diversity drops and butyrate-producing guilds are depleted, the mucosa may become more vulnerable to luminal antigens and inflammatory signaling, even when diagnostic findings do not clearly separate the disease into Crohn’s disease or ulcerative colitis.

Functionally, the diversity shift in IBD-U is also associated with altered metabolic outputs from the microbial community, not just changes in who is present. With disrupted fermentation pathways and weakened SCFA production, the intestinal environment can become less regulatory and more pro-inflammatory, affecting immune tolerance mechanisms. This microbiome instability and functional remodeling can contribute to overlapping “Crohn’s-like” and “colitis-like” patterns, which may help explain why IBD-U remains unclassified while symptoms can persist or flare.


Order Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription

Why generic solutions fail

  • Issue with generic solutions

    Generic solutions often fail in IBD-unclassified (IBD-U) because the condition is defined by uncertainty—many patients display a dysbiotic microbiome that doesn’t consistently resemble classic Crohn’s or ulcerative colitis. This means a one-size-fits-all approach (such as applying the same dietary template or supplement stack to everyone) can miss the patient’s dominant functional issue, whether it’s impaired fiber fermentation and short-chain fatty acid (SCFA) production, altered bile-acid metabolism, or shifts in immune-modulating microbial signals. When the underlying functional imbalance isn’t addressed, symptoms like diarrhea, abdominal pain, bloating, and fatigue can persist even if the intervention seems “in line” with general IBD guidance.

    A second reason generic strategies underperform is that microbiome harm in IBD-U often involves ecosystem-level changes, not just a single organism to suppress or a single nutrient to add. Reduced diversity and depletion of barrier-supporting, butyrate-producing microbes can weaken mucus integrity, epithelial tight-junction stability, and the gut’s resilience to luminal stress. Generic prebiotic “boosters” or broad antimicrobial-style approaches may worsen symptoms in some patients by shifting fermentation patterns unpredictably or disrupting residual beneficial communities further. Without personalization, patients may inadvertently increase gas and fermentation byproducts, fail to restore the specific metabolic pathways that generate SCFAs, or trigger antigen/immune interactions that sustain inflammation.

    Finally, IBD-U frequently shows overlap between Crohn’s-like and colitis-like biology, which can make standard protocols that assume a single pathway of inflammation less effective. Treatments that don’t account for variability in microbial metabolite profiles (including SCFAs and bile-acid–related signaling) may not reliably shift immune balance toward tolerance. As a result, generic interventions can lead to mixed or transient responses—improving symptoms temporarily while failing to reduce the flare risk drivers rooted in dysbiosis, functional metabolism, and immune–microbe crosstalk.

  • Common mistakes

    • Using a one-size-fits-all diet template without tailoring to the patient’s dominant functional deficit (e.g., impaired fiber fermentation/SCFA output vs altered bile-acid metabolism vs altered immune-modulating metabolite signaling).
    • Starting broad prebiotics or high-fiber “boosters” indiscriminately, which can increase gas and fermentation byproducts, worsen bloating/diarrhea, and unpredictably shift fermentation away from beneficial SCFA (especially butyrate) pathways.
    • Employing generic antimicrobial-style strategies (or overly aggressive suppression) without regard to ecosystem-level dysbiosis risk, potentially further depleting residual beneficial, barrier-supporting microbes.
    • Assuming symptoms directly reflect inflammation subtype (Crohn’s-like vs colitis-like) when IBD-U often shows mixed overlap, leading to interventions that don’t address the specific metabolite/immune–microbe drivers in that patient.
    • Overlooking restoration of barrier-supporting functions (mucus layer, epithelial tight junction integrity, butyrate availability) and instead focusing only on symptom relief (e.g., reducing stool frequency) rather than rebuilding microbial metabolic function.
    • Ignoring bile-acid and microbial metabolite signaling changes (secondary bile acids, antigen handling, Treg/tolerance pathways), and therefore not aligning the plan to the patient’s likely immune–microbe crosstalk mechanism.
    • Treating microbiome “composition” as the target rather than microbiome function, missing that two patients can have similar symptoms but different dysbiotic functional outputs (SCFA, fermentation pathways, bile-acid transformations).
    • Failing to account for individual tolerance and timing (starting too fast, not stepping doses, not monitoring response), which can create transient improvement followed by persistent flare susceptibility when the underlying metabolic imbalance remains.

What to do

  • General support strategies

    For IBD-unclassified (IBD-U), general gut-support strategies often focus on restoring a healthier microbial balance and supporting the intestinal barrier while symptoms are managed. Since microbiome research in IBD-U commonly shows reduced diversity and fewer butyrate-producing organisms, diet and lifestyle interventions that promote beneficial fermentation pathways can be helpful. In practice, this may mean emphasizing fiber-rich, gut-tolerable carbohydrates (especially those that feed beneficial microbes), staying consistent with meal patterns, and adjusting fiber type or overall intake based on individual tolerance—particularly during flares.

    Functional microbiome support also targets inflammatory signaling and mucus/epithelial resilience. Short-chain fatty acids—especially butyrate—are key products of microbial fermentation that help maintain the mucus layer and support epithelial tight junction integrity. Strategies that support butyrate production may include adequate protein and overall calorie intake, careful inclusion of prebiotic fibers or polyphenol-rich foods, and hydration. Where diet alone is insufficient or symptoms limit intake, some people consider clinician-guided options such as targeted prebiotics, probiotics, or other microbiome-modulating approaches, with the goal of improving microbial function rather than relying on any single “one-size-fits-all” product.

    Because IBD-U can evolve and may show mixed microbiome signatures over time, support approaches are frequently paired with personalized monitoring. Tracking symptom patterns, stool characteristics, and food triggers can help guide ongoing adjustments to diet and gut-care habits. Functional biomarker trends and/or microbiome-informed insights may also support treatment decisions and help identify flare risk, allowing for earlier, more tailored nutritional and lifestyle changes aimed at improving gut healing and long-term tolerance.

  • Lifestyle recommendations

    • Adopt a fiber-forward, gut-tolerant diet (e.g., gradually increase soluble fiber like oats, bananas, and cooked/peeled fruits/vegetables) to support butyrate-producing fermentation; adjust during flares as needed.
    • Prioritize adequate protein and calories, and limit ultra-processed foods and high-sugar emulsifiers that may worsen dysbiosis; consider keeping a symptom/food journal to identify triggers.
    • Reduce dietary fat and irritant exposures if they worsen symptoms (e.g., limit fried/very fatty meals, alcohol, and excessive caffeine) while maintaining overall nutrition.
    • Use stress-reduction practices (e.g., mindfulness, CBT tools, yoga, or breathing exercises) since gut–immune signaling can amplify symptom flares.
    • Maintain regular physical activity within your tolerance (e.g., walking) to support motility, metabolic health, and anti-inflammatory pathways.
    • Avoid unnecessary antibiotics and other microbiome-disrupting medications when possible; discuss timing/necessity with your clinician.
    • Consider probiotic or prebiotic strategies selectively (only if tolerated and in discussion with your gastroenterologist), focusing on gradual introduction of gut-supporting options rather than rapid high-dose changes.

  • Nutrition recommendations

    • Prioritize a high-fiber, plant-forward diet as tolerated (target gradually toward ~25–35 g/day), emphasizing soluble fibers (oats, chia, ground flax, psyllium) to support mucosal barrier function and butyrate production; reduce insoluble/fiber-heavy foods during flares or if symptoms worsen.
    • Increase butyrate-supporting carbohydrates (prebiotic “food” for beneficial microbes) such as oats, barley, legumes (if tolerated), onions, garlic, and cooked/cooled potatoes/rice; start low and adjust to tolerance to avoid gas/bloating.
    • Ensure adequate protein intake (e.g., eggs, poultry, fish, yogurt/kefir if tolerated, tofu/tempeh) to support intestinal repair—choose lean, easily digested options during active symptoms.
    • Use an elimination-and-rechallenge approach for common symptom triggers (often high-FODMAP foods, lactose, sugar alcohols, and very fatty/fried foods); consider a temporary low-FODMAP phase with dietitian guidance to reduce dysbiosis-related fermentation symptoms.
    • Consider fermented foods in moderation if tolerated (unsweetened yogurt/kefir, sauerkraut/kimchi) to support microbial diversity; avoid during acute flares if they worsen stool frequency or pain.
    • Hydrate well and replace electrolytes during diarrhea; choose gentle, bland meal patterns when symptomatic (e.g., rice, bananas, oats, soups) while maintaining micronutrient adequacy.
    • Avoid ultra-processed foods and excess added sugars, which are associated with poorer gut microbiome profiles and may amplify inflammatory signaling through altered microbial metabolism.

  • Supplement considerations

    For IBD-unclassified (IBD-U), supplement choices are often aimed at supporting intestinal barrier integrity, calming dysregulated immune signaling, and improving microbial metabolic function—especially when research suggests reduced microbial diversity and fewer butyrate-producing organisms. Because butyrate is a key short-chain fatty acid involved in maintaining the mucus layer and epithelial tight junctions, strategies that support fermentation and beneficial metabolite production may be considered. This can include targeted fiber and prebiotic approaches chosen to be tolerable in active symptoms, alongside supplementation designed to reduce gut irritation and support a healthier microbial ecosystem.

    Probiotic and postbiotic options may also be relevant, particularly when the goal is to increase beneficial community members or stabilize microbial activity without relying solely on “active” organisms that may vary between individuals. In IBD-U, where biology can overlap Crohn’s- and colitis-like features, the immune-modulating effects of certain strains and microbial metabolites (postbiotics) may help support a more balanced inflammatory tone. Some people may benefit from adjuncts that provide anti-inflammatory properties or help neutralize oxidative stress, but responses can be highly individual—so product selection, dosing, and symptom tracking matter.

    Because active IBD-U symptoms (diarrhea, abdominal pain, bloating, fatigue) can be sensitive to supplementation, it’s also important to prioritize tolerability and safety. Supplements that can worsen gas or cramping—especially those that rapidly ferment—may need cautious introduction or dose adjustment. Finally, many supplement considerations work best when paired with overall nutrition adequacy and, when possible, guidance from a clinician, since deficiencies (such as vitamin D, iron, or B vitamins) can coexist and influence immune function and recovery. Functional biomarker monitoring and personalized trialing can help refine which microbiome-supporting supplements are most likely to support gut healing for your specific pattern.

  • Retesting / monitoring note

    For IBD-unclassified (IBD-U), retesting is often recommended when symptoms persist, when initial testing is inconclusive, or when there are changes in clinical course that could suggest a shift toward Crohn’s disease or ulcerative colitis. Because IBD-U is associated with characteristic gut dysbiosis—often including reduced microbial diversity and fewer butyrate-producing organisms—repeat evaluation can help determine whether the microbiome pattern and its functional potential (such as short-chain fatty acid production) are remaining stable, improving, or worsening over time. Retesting may be timed around changes in treatment, diet, stool frequency, or the presence of flare-like symptoms, to better capture cause-and-effect rather than one-off results.

    In addition to repeating stool-based microbiome or functional analyses, retesting for intestinal inflammation and barrier function can support interpretation of microbiome findings. Functional readouts that reflect microbial metabolism (for example, pathways linked to fermentation and short-chain fatty acid generation) are especially useful because they may explain why symptoms continue even when standard endoscopic or biopsy findings do not clearly classify the disease. Repeating relevant biomarkers alongside microbiome results can help clarify whether dysbiosis is accompanied by ongoing inflammatory signaling, which in turn can inform more personalized nutritional or microbiome-targeted strategies aimed at restoring resilience of the mucus layer and epithelial tight junctions.

    Finally, retesting is recommended to guide risk stratification and treatment responsiveness in IBD-U, since microbiome patterns can overlap with both Crohn’s-like and colitis-like biology. Many clinicians consider repeating testing after a defined intervention period (such as a gut-healing nutrition protocol or targeted therapies) to assess trajectory—whether the microbial ecosystem is moving toward a more diverse, metabolically favorable community. Consistent retesting can also help determine if further diagnostic refinement is needed, supporting timely reclassification and optimization of long-term management.

The importance of gut microbiome testing

  • Why testing matters

    Gut microbiome testing matters in IBD-unclassified (IBD-U) because it can uncover dysbiosis patterns that may not be fully captured by standard endoscopy or biopsy early in disease. Even when the condition hasn’t clearly separated into Crohn’s disease or ulcerative colitis, microbiome profiling can reveal reduced microbial diversity and shifts away from key protective groups—such as butyrate-producing organisms—that support gut barrier integrity and immune tolerance. Identifying these changes helps clinicians better understand the biological “terrain” driving symptoms and flare susceptibility.

    Testing also matters because it goes beyond who is present to what microbes are doing. Functional readouts can highlight disruptions in fermentation pathways that influence short-chain fatty acid (SCFA) production, particularly butyrate, which helps maintain the mucus layer, supports epithelial tight junctions, and dampens inflammatory signaling. When SCFA output is impaired, the gut lining may become more vulnerable to luminal triggers, potentially contributing to ongoing diarrhea, abdominal cramping, bloating, and fatigue. By mapping these functional deficits, microbiome tests can provide actionable context for diet and gut-healing strategies rather than relying only on clinical presentation.

    Finally, microbiome testing may support more personalized treatment planning by helping stratify patients by likely trajectory and treatment responsiveness. In IBD-U, microbiome signals can reflect overlapping Crohn’s-like and colitis-like biology, which may explain why patients remain unclassified initially. Using microbial community structure and functional biomarkers can therefore help refine risk assessment and guide microbiome-targeted nutrition or adjunct therapies designed to restore beneficial metabolic activity and reduce inflammatory tone.

  • How InnerBuddies helps

    In IBD-unclassified (IBD-U), symptoms and early findings may not clearly fit Crohn’s disease or ulcerative colitis, but the gut microbiome can still show a distinct pattern of dysbiosis. The InnerBuddies test helps by profiling the microbial community living in the gut, looking for shifts associated with lower diversity and reduced abundance of protective groups—especially those involved in producing beneficial short-chain fatty acids like butyrate. Because these metabolites support the intestinal barrier, mucus integrity, and immune tolerance, detecting these microbiome “weak points” can clarify why inflammation and GI symptoms may persist even when classification is still uncertain.

    InnerBuddies also adds value by focusing on what the microbiome is likely doing, not only which organisms are present. In IBD-U, fermentation pathways may be disrupted, which can mean less butyrate and other SCFAs that normally help maintain epithelial tight junctions and calm inflammatory signaling. By highlighting functional deficits related to microbial metabolism, the test can provide actionable context for understanding potential drivers of diarrhea, abdominal cramping, bloating, and fatigue—supporting gut-healing strategies aimed at restoring more resilient metabolic activity.

    Finally, microbiome insights from InnerBuddies can support more personalized planning in IBD-U by helping stratify patients by biological patterns that may relate to flare susceptibility and treatment responsiveness. Since microbiome signals can reflect overlapping “Crohn’s-like” and “colitis-like” biology early on, the results may help refine risk and guide adjunct approaches such as nutrition adjustments or microbiome-targeted interventions. This can make management more tailored to the underlying gut environment while clinicians continue to monitor disease evolution and classification.

Medical Evidence

  • Scientific evidence level

    2 [weak (emerging but inconsistent) — microbiome alterations are biologically plausible and frequently observed in IBD-unclassified, but robust causality and clinically validated utility are lacking]

  • Clinical relevance note

    At present, microbiome data for IBD-unclassified should be viewed as supportive rather than determinative. Statistically significant dysbiosis patterns are frequently reported in IBD (including indeterminate or early phenotypes), but these patterns are not consistently specific to IBDU, and effect sizes and directionality vary across studies due to methodological inconsistency (sampling site, sequencing platform, bioinformatics pipeline, batch effects) and clinical confounding (medications, diet, inflammatory activity, and microbiome-modifying exposures). Reverse causality is likely because active gut inflammation itself reshapes the microbiome.

    There is not yet convincing evidence that measuring the gut microbiome improves real-world outcomes in IBDU—e.g., reliably confirming diagnosis, predicting whether a patient will later convert to UC vs CD, selecting an optimal therapy, or improving monitoring. While microbiome-modulating interventions can alter microbial composition and sometimes correlate with clinical improvement in subsets of IBD populations, IBDU-specific trials with clinically meaningful endpoints are lacking. Consequently, current clinical relevance is limited to research/biomarker discovery contexts rather than validated clinical decision-making.

Title Journal Year Link
The gut microbiome and mucosal immune responses in inflammatory bowel disease Cell 2019 View →
Dysbiosis and bacterial metabolites in ulcerative colitis and Crohn's disease Nature Reviews Immunology 2016 View →
Gut microbiota in inflammatory bowel disease: a systematic review and meta-analysis Nature Reviews Gastroenterology & Hepatology 2014 View →
Diet rapidly and reproducibly alters the human gut microbiome Nature 2014 View →
Characterization of the gut microbiota in treatment-naive patients with Crohn's disease Proceedings of the National Academy of Sciences of the United States of America (PNAS) 2007 View →

Frequently Asked Questions

    ¿Qué es la EII-U y en qué se diferencia de la enfermedad de Crohn y la colitis ulcerosa?
    La EII-U es una enfermedad inflamatoria intestinal que aún no cumple claramente los criterios de CD o UC; la clasificación puede cambiar con el tiempo a medida que se obtiene más información.
    ¿Cómo se relaciona el microbioma intestinal con la EII-U?
    El microbioma puede influir en la inflamación y los síntomas; se observan patrones como menor diversidad y cambios en funciones metabólicas clave como la producción de butirato.
    ¿Qué significa disbiosis en la EII-U?
    Disbiosis es un desequilibrio de la comunidad microbiana intestinal, no un patógeno; a menudo hay menos microbios beneficiosos y más microbios potencialmente inflamatorios.
    ¿Por qué son importantes las bacterias productoras de butirato?
    El butirato ayuda a mantener la barrera intestinal y regula la respuesta inmunitaria; su pérdida puede debilitar la mucosa y la barrera.
    ¿Qué síntomas son comunes en la EII-U?
    Diarrea crónica o recurrente, dolor abdominal, sangre o mucosidad en las heces, pérdida de peso, fatiga; la fiebre puede ocurrir durante brotes.
    ¿Qué tan común es la EII-U entre los pacientes con EII?
    Es una minoría, a menudo alrededor del 5–15%, y varía por región y seguimiento.
    ¿Los tests del microbioma pueden ayudar a predecir brotes o guiar el tratamiento?
    Pueden revelar patrones asociados con la actividad y el riesgo, pero no sustituyen un diagnóstico clínico definitivo.
    ¿Cuál es el papel de terapias o nutrición orientadas al microbioma en la EII-U?
    Las estrategias nutricionales y dirigidas al microbioma están en estudio; las decisiones deben ser tomadas con el equipo de atención.
    ¿Qué mide la prueba InnerBuddies y en qué es útil?
    Perfil de microbios y vías funcionales (p. ej., producción de SCFA) para identificar disbiosis y déficits metabólicos relevantes.
    ¿Qué patrones microbianos típicos se observan en la EII-U?
    Diversidad reducida, menos productores de butirato y cambios hacia taxones proinflamatorios; también hay cambios metabólicos.
    ¿Existen riesgos o limitaciones en las pruebas del microbioma?
    Sí; la ciencia está en evolución; los resultados pueden variar y no todas las pruebas están validadas clínicamente.
    ¿Cómo discutir estos resultados con mi médico?
    Lleva el informe y considérelo parte del cuadro general junto con síntomas y otras pruebas; úsenlo para decisiones compartidas.
    ¿Puedo influir en mi microbioma solo con la dieta?
    La dieta puede influir, pero los resultados varían y los cambios toman tiempo; normalmente se recomienda una dieta variada y rica en fibra; consulta con un médico.
    ¿Es probable que la EII-U se convierta en CD o UC con el tiempo?
    A menudo la clasificación se aclara con el tiempo, pero no hay garantía.
    ¿Cuáles son las limitaciones de la investigación actual sobre el microbioma en la EII-U?
    Muchos estudios son observacionales y hay heterogeneidad entre pacientes; se necesitan más estudios grandes y consistentes.

    Hear from our satisfied customers!

    • "I would like to let you know how excited I am. We had been on the diet for about two months (my husband eats with us). We felt better with it, but how much better was really only noticed during the Christmas vacations when we had received a large Christmas package and didn't stick to the diet for a while. Well that did give motivation again, because what a difference in gastrointestinal symptoms but also energy in both of us!"

      - Manon, age 29 -

    • "Super help!!! I was already well on my way, but now I know for sure what I should and should not eat, drink. I have been struggling with stomach and intestines for so long, hope I can get rid of it now."

      - Petra, age 68 -

    • "I have read your comprehensive report and advice. Many thanks for that and very informative. Presented in this way, I can certainly move forward with it. Therefore no new questions for now. I will gladly take your suggestions to heart. And good luck with your important work."

      - Dirk, age 73 -